CliffBio
biologic

Imdelltra

tarlatamab-dlle

Loss of exclusivityMay 2036projected — 12-year biologic exclusivity estimate
CompanyAmgen →View the full company profile on CliffBio

Drug detail

Brand nameImdelltra
Active ingredienttarlatamab-dlle
Strength10MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2024
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Imdelltra patent cliff — loss of exclusivity May 2036 | CliffBio